Dong Sung Bio Pharm.Co.,Ltd. (002210.KS)
KRW 5320.0
(1.92%)
KRW 5320.0
(1.92%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 75.17 Billion KRW | 15.84% |
| 2022 | 64.89 Billion KRW | 11.61% |
| 2021 | 58.14 Billion KRW | -17.84% |
| 2020 | 70.77 Billion KRW | 14.83% |
| 2019 | 61.63 Billion KRW | -25.49% |
| 2018 | 82.71 Billion KRW | 38.05% |
| 2017 | 59.91 Billion KRW | -14.12% |
| 2016 | 69.76 Billion KRW | 5.1% |
| 2015 | 66.38 Billion KRW | -15.61% |
| 2014 | 78.65 Billion KRW | 19.89% |
| 2013 | 65.61 Billion KRW | -7.27% |
| 2012 | 70.75 Billion KRW | 9.9% |
| 2011 | 64.37 Billion KRW | -6.51% |
| 2010 | 68.85 Billion KRW | 14.89% |
| 2009 | 59.93 Billion KRW | 5.62% |
| 2008 | 56.74 Billion KRW | -0.93% |
| 2007 | 57.27 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 85.01 Billion KRW | 8.17% |
| 2024 Q1 | 78.58 Billion KRW | 4.55% |
| 2023 Q4 | 75.17 Billion KRW | -4.23% |
| 2023 Q3 | 78.48 Billion KRW | 10.78% |
| 2023 FY | 75.17 Billion KRW | 15.84% |
| 2023 Q2 | 70.85 Billion KRW | 8.69% |
| 2023 Q1 | 65.18 Billion KRW | 0.45% |
| 2022 Q2 | 64.48 Billion KRW | 0.28% |
| 2022 Q1 | 64.3 Billion KRW | 10.6% |
| 2022 FY | 64.89 Billion KRW | 11.61% |
| 2022 Q4 | 64.89 Billion KRW | 0.08% |
| 2022 Q3 | 64.83 Billion KRW | 0.55% |
| 2021 Q1 | 67.66 Billion KRW | -4.39% |
| 2021 Q3 | 60.83 Billion KRW | 11.53% |
| 2021 Q4 | 58.14 Billion KRW | -4.43% |
| 2021 FY | 58.14 Billion KRW | -17.84% |
| 2021 Q2 | 54.54 Billion KRW | -19.39% |
| 2020 Q1 | 70.07 Billion KRW | 13.7% |
| 2020 FY | 70.77 Billion KRW | 14.83% |
| 2020 Q2 | 71.83 Billion KRW | 2.51% |
| 2020 Q4 | 70.77 Billion KRW | -2.84% |
| 2020 Q3 | 72.83 Billion KRW | 1.39% |
| 2019 Q2 | 66.32 Billion KRW | -22.83% |
| 2019 Q3 | 67.54 Billion KRW | 1.83% |
| 2019 Q4 | 61.63 Billion KRW | -8.75% |
| 2019 FY | 61.63 Billion KRW | -25.49% |
| 2019 Q1 | 85.95 Billion KRW | 3.92% |
| 2018 Q4 | 82.71 Billion KRW | -20.01% |
| 2018 Q1 | 60.98 Billion KRW | 1.78% |
| 2018 FY | 82.71 Billion KRW | 38.05% |
| 2018 Q2 | 78.35 Billion KRW | 28.49% |
| 2018 Q3 | 103.4 Billion KRW | 31.97% |
| 2017 Q2 | 68.91 Billion KRW | 4.64% |
| 2017 Q4 | 59.91 Billion KRW | -10.82% |
| 2017 FY | 59.91 Billion KRW | -14.12% |
| 2017 Q3 | 67.18 Billion KRW | -2.5% |
| 2017 Q1 | 65.85 Billion KRW | -5.61% |
| 2016 Q3 | 72.41 Billion KRW | 2.27% |
| 2016 Q4 | 69.76 Billion KRW | -3.65% |
| 2016 Q1 | 67.98 Billion KRW | 2.42% |
| 2016 FY | 69.76 Billion KRW | 5.1% |
| 2016 Q2 | 70.8 Billion KRW | 4.14% |
| 2015 Q1 | 76.46 Billion KRW | -2.79% |
| 2015 Q4 | 66.38 Billion KRW | -11.65% |
| 2015 Q3 | 75.13 Billion KRW | -1.72% |
| 2015 FY | 66.38 Billion KRW | -15.61% |
| 2015 Q2 | 76.44 Billion KRW | -0.03% |
| 2014 Q2 | 66.28 Billion KRW | 0.42% |
| 2014 FY | 78.65 Billion KRW | 19.89% |
| 2014 Q4 | 78.65 Billion KRW | 12.16% |
| 2014 Q3 | 70.13 Billion KRW | 5.8% |
| 2014 Q1 | 66.01 Billion KRW | 0.61% |
| 2013 Q3 | 67.89 Billion KRW | -1.37% |
| 2013 Q4 | 65.61 Billion KRW | -3.36% |
| 2013 FY | 65.61 Billion KRW | -7.27% |
| 2013 Q2 | 68.83 Billion KRW | -1.8% |
| 2013 Q1 | 70.09 Billion KRW | -0.93% |
| 2012 Q1 | 71.22 Billion KRW | 0.0% |
| 2012 FY | 70.75 Billion KRW | 9.9% |
| 2012 Q4 | 70.75 Billion KRW | -3.9% |
| 2012 Q3 | 73.62 Billion KRW | -1.0% |
| 2012 Q2 | 74.36 Billion KRW | 4.41% |
| 2011 FY | 64.37 Billion KRW | -6.51% |
| 2011 Q3 | 67.46 Billion KRW | 4.43% |
| 2011 Q2 | 64.6 Billion KRW | -7.16% |
| 2011 Q1 | 69.58 Billion KRW | 1.06% |
| 2010 Q1 | 65.33 Billion KRW | 9.01% |
| 2010 FY | 68.85 Billion KRW | 14.89% |
| 2010 Q4 | 68.85 Billion KRW | -4.96% |
| 2010 Q3 | 72.45 Billion KRW | 5.28% |
| 2010 Q2 | 68.81 Billion KRW | 5.33% |
| 2009 Q4 | 59.93 Billion KRW | 3.14% |
| 2009 FY | 59.93 Billion KRW | 5.62% |
| 2009 Q2 | 61.61 Billion KRW | 6.45% |
| 2009 Q1 | 57.88 Billion KRW | 2.0% |
| 2009 Q3 | 58.11 Billion KRW | -5.69% |
| 2008 Q1 | 53.16 Billion KRW | -7.19% |
| 2008 Q3 | 51.22 Billion KRW | -2.37% |
| 2008 FY | 56.74 Billion KRW | -0.93% |
| 2008 Q4 | 56.74 Billion KRW | 10.78% |
| 2008 Q2 | 52.46 Billion KRW | -1.31% |
| 2007 Q1 | 58.93 Billion KRW | 0.0% |
| 2007 Q3 | 59.07 Billion KRW | -0.24% |
| 2007 Q2 | 59.21 Billion KRW | 0.47% |
| 2007 FY | 57.27 Billion KRW | 0.0% |
| 2007 Q4 | 57.27 Billion KRW | -3.04% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 77.85 Billion KRW | 3.451% |
| Dong-A Socio Holdings Co., Ltd. | 929.79 Billion KRW | 91.915% |
| Ildong Holdings Co., Ltd. | 707.09 Billion KRW | 89.369% |
| HANDOK Inc. | 449.7 Billion KRW | 83.284% |
| Kukje Pharma Co., Ltd. | 85.67 Billion KRW | 12.256% |
| Yuhan Corporation | 712.33 Billion KRW | 89.447% |
| Dong-A ST Co., Ltd. | 631.91 Billion KRW | 88.104% |
| SAMSUNG PHARM. Co., LTD. | 15.89 Billion KRW | -372.937% |
| Hanmi Pharm. Co., Ltd. | 851.82 Billion KRW | 91.175% |
| Hanall Biopharma Co.,Ltd | 53.52 Billion KRW | -40.431% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | 63.487% |
| MYUNGMOON Pharm co.,Ltd | 147.79 Billion KRW | 49.138% |
| Hana Pharm Co., Ltd. | 70.4 Billion KRW | -6.775% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | 3.451% |
| Ilsung Pharmaceuticals Co., Ltd. | 36.43 Billion KRW | -106.308% |
| REYON Pharmaceutical Co., Ltd. | 251.15 Billion KRW | 70.069% |
| Aprogen pharmaceuticals,Inc. | 220.7 Billion KRW | 65.941% |
| JW Holdings Corporation | 827.51 Billion KRW | 90.916% |
| Ildong Pharmaceutical Co., Ltd. | 436.99 Billion KRW | 82.798% |
| Chong Kun Dang Pharmaceutical Corp. | 586.79 Billion KRW | 87.19% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 80.197% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | 5.209% |
| Hyundai Pharmaceutical Co., Ltd. | 69.96 Billion KRW | -7.437% |
| Samil Pharmaceutical Co.,Ltd | 242.85 Billion KRW | 69.047% |
| Jeil Pharmaceutical Co.,Ltd | 330.29 Billion KRW | 77.241% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | 3.451% |
| Kwang Dong Pharmaceutical Co., Ltd. | 490.01 Billion KRW | 84.66% |
| Daewoong pharmaceutical Co.,Ltd | 858.02 Billion KRW | 91.239% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 80.197% |
| Yuhan Corporation | 712.33 Billion KRW | 89.447% |
| Jeil Pharma Holdings Inc | 477.81 Billion KRW | 84.268% |
| Yungjin Pharm. Co., Ltd. | 136.96 Billion KRW | 45.118% |
| Suheung Co., Ltd. | 516.66 Billion KRW | 85.451% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 80.197% |
| Samjin Pharmaceuticals Co., Ltd. | 154.53 Billion KRW | 51.357% |
| Korea United Pharm Inc. | 89.96 Billion KRW | 16.445% |
| CKD Bio Corp. | 170.76 Billion KRW | 55.979% |
| Daewon Pharmaceutical Co., Ltd. | 243.73 Billion KRW | 69.159% |
| Dongwha Pharm.Co.,Ltd | 157.65 Billion KRW | 52.32% |
| Whan In Pharm Co.,Ltd. | 43.01 Billion KRW | -74.738% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | 5.209% |
| Chong Kun Dang Holdings Corp. | 632.51 Billion KRW | 88.116% |
| Boryung Corporation | 373.1 Billion KRW | 79.853% |
| Bukwang Pharmaceutical Co., Ltd. | 208.19 Billion KRW | 63.894% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | 63.487% |
| JW Lifescience Corporation | 96.44 Billion KRW | 22.057% |